Self-amplifying RNA vaccine protects mice against lethal Ebola virus infection

Mol Ther. 2023 Feb 1;31(2):374-386. doi: 10.1016/j.ymthe.2022.10.011. Epub 2022 Oct 27.


Emerging and re-emerging viruses, such as Zaire Ebola virus (EBOV), pose a global threat and require immediate countermeasures, including the rapid development of effective vaccines that are easy to manufacture. Synthetic self-amplifying RNAs (saRNAs) attend to these needs, being safe and strong immune stimulators that can be inexpensively produced in large quantities, using cell-free systems and good manufacturing practice. Here, the first goal was to develop and optimize an anti-EBOV saRNA-based vaccine in terms of its antigen composition and route of administration. Vaccinating mice with saRNAs expressing the EBOV glycoprotein (GP) alone or in combination with the nucleoprotein (NP) elicited antigen-specific immune responses. GP-specific antibodies showed neutralizing activity against EBOV. Strong CD4+ T cell response against NP and GP and CD8+ T cell response against NP were detected by ELISpot assays. Intramuscular vaccination with saRNAs conferred better immune response than intradermal. Finally, mice vaccinated in a prime-boost regimen with saRNAs encoding both GP and NP or with GP alone survived an EBOV infection. In addition, a single dose of GP and NP saRNAs was also protective against fatal EBOV infection. Overall, saRNAs expressing viral antigens represent a promising vaccine platform.

Keywords: Ebola virus; combination of saRNAs; glycoprotein; lipid nanoparticles; nucleoprotein; self-amplifying RNA; vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Ebola Vaccines* / genetics
  • Ebolavirus* / genetics
  • Glycoproteins / genetics
  • Hemorrhagic Fever, Ebola* / prevention & control
  • Mice


  • Antibodies, Viral
  • Antibodies, Neutralizing
  • Glycoproteins
  • Ebola Vaccines